Fairmount Funds Management LLC: APOGEE THERAPEUTICS INC (APGE): Quarterly 13F Position History
As of Q2 2026, Fairmount Funds Management LLC reported 298,647 shares of APOGEE THERAPEUTICS INC (APGE), worth $39.6M and representing 2.6% of its 13F equity book. The position first appeared in Q3 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 298,647Shares Held (Latest Filing)
- $39.6MReported Market Value (Latest Filing)
- 2.6%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$14.5MQuarter-over-Quarter Value Change
- 2,941,176Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 298,647 | 0 | – | $39.6M | 2.6% | $132.7 |
| Q1 2026 | 298,647 | 1,750,000 | -85.4% | $25.1M | 1.8% | $84.2 |
| Q4 2025 | 2,048,647 | 0 | – | $154.6M | 11.8% | $75.5 |
| Q3 2025 | 2,048,647 | 0 | – | $81.4M | 7.3% | $39.7 |
| Q2 2025 | 2,048,647 | 0 | – | $89.0M | 11.5% | $43.4 |
| Q1 2025 | 2,048,647 | 0 | – | $76.5M | 11.9% | $37.4 |
| Q4 2024 | 2,048,647 | 0 | – | $92.8M | 9.2% | $45.3 |
| Q3 2024 | 2,048,647 | 0 | – | $120.3M | 9.8% | $58.7 |
| Q2 2024 | 2,048,647 | 0 | – | $80.6M | 9.1% | $39.4 |
| Q1 2024 | 2,048,647 | 892,529 | -30.3% | $136.1M | 14.8% | $66.5 |
| Q4 2023 | 2,941,176 | 0 | – | $82.2M | 8.7% | $27.9 |
| Q3 2023 | 2,941,176 | – | – | $62.6M | 7.5% | $21.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Fairmount Funds Management LLC first disclose a APGE position in 13F-HR filings?
Fairmount Funds Management LLC first reported APOGEE THERAPEUTICS INC (APGE) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in APGE?
Fairmount Funds Management LLC held the same 298,647 shares of APGE between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in APGE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.